Successful Investor

Hotels

  • Investments in Grand Bohemian Hotels
  • Partner with Richard C. Kessler, an entrepreneur in the field of hotel development and operations. 
  • Kessler has been Chairman and CEO of The Kessler Enterprise, Inc. since 1984. He is also Former Chairman, President, and CEO, Days Inn of America, Inc. and Former Chairman of Lutheran Brotherhood. 

Richard C. Kessler CEO  The Kessler Enterprise, Inc. and Dr. Charles Richardson


Fundraising

  • Raised millions of dollars for over 30 companies
  • Raised money for TransWorld Heart, Cleveland Heart, Cleveland Diabetes Care, TransWorld Kidney, RIVA Med, BioPulse Medical, CCC Medical, and American Heart Association 51st Annual Charlotte Heart. 
 Chris Kim J.D. and Dr. Charles Richardson on Wall Street with a Healthcare Investment Banker

Chris Kim J.D. and Dr. Charles Richardson on Wall Street with a Healthcare Investment Banker


 Chris Kim J.D., Donald Trump Jr., and Dr. Charles Richardson building healthcare innovation together. 

Chris Kim J.D., Donald Trump Jr., and Dr. Charles Richardson building healthcare innovation together. 

Greatbatch, inc.

  • Greatbatch, Inc. acquired TransWorld Heart manufacturer CCC Medical Device. 

Greatbatch, Inc. (GB - Analyst Report) acquired CCC Medical Devices, a Uruguay-based developer and manufacturer of active implantable medical (AIMD) systems, in an effort to partner with more medical device companies and complement its core discrete technology offerings. The financial terms of the transaction were kept under wraps.


Located in Montevideo, CCC Medical Devices designs and produces a range of devices for medical device companies all over the world, including implantable pulse generators, programmer systems, battery chargers, patient wands and leads.

With the acquisition of CCC Medical Devices, GB aims to enhance its medical device innovation efforts. Combining the knowledge, talent and customer base of both companies, GB hopes to produce better products for the medical community and improve the lives of people worldwide.


Medtronic

  • Medtronic to Acquire Biophan MRI Safety Technology for $11 Million

PITTSFORD, NY--(Marketwire - August 9, 2007) - Biophan Technologies, Inc., a developer of next-generation biomedical technology, today announced that the Company has entered into a definitive agreement with Medtronic, Inc. to acquire Biophan's MRI safety patents in a transaction worth $11 million in cash. The transaction had anticipated to close within 60 days and had done so successfully.

Under the terms of the agreement, Biophan will transfer to Medtronic its MRI safety patent portfolio, which includes technologies that make medical devices, such as pacemakers, safe for use with MRI.

"Since our founding in 2000, the goal has been to develop and commercialize innovative technologies related to medical imaging safety, with a focus on the development of solutions for the contraindication between pacemakers and MRI machines," stated Mr. Guenter Jaensch, Chairman of Biophan's Board of Directors.

"Our technology has the potential to solve the problems that have prevented many people with pacemakers from having an MRI. We believe Medtronic has the experience and resources to bring our technology to market," stated Michael Weiner, President of Biophan.

Biophan will continue its efforts to develop technologies to enable visualization of clotting and restenosis in stents under MRI, which is not possible with today's stents. In addition, it will continue its collaboration with Myotech on the development of the Myotech Circulatory Support System, a novel device for the treatment of acute heart failure.

About Biophan Technologies, Inc.:

Biophan is dedicated to providing technologies that offers innovative and competitive advantages to the medical device industry. In addition, the Company is helping to commercialize Myotech's new cardiac support system which has significant potential to improve the treatment of many forms of heart disease. Biophan Technologies, Inc. holds a 45% interest in Myotech with rights to acquire a majority position, and is leading Myotech's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN.